SHANGHAI – The Center for Drug Evaluation (CDE) of the China Food and Drug Administration (CFDA) has released its annual report for 2013 which reveals only small gains have been made to fix the slow and overcrowded approval process.
SHANGHAI – In 2013, venture capital (VC) activity in China’s life sciences sector remained strong, dipping only slightly below the year previous. Investor enthusiasm did not diminish even when China barred companies from holding initial public offerings (IPO) here, the exit of choice for VCs.
SHANGHAI – After a year of revisions, China’s Ministry of Commerce (MOFCOM) revealed its anticipated new “simple rules” for mergers and acquisitions. The move signals the government’s intentions toward fast-tracking deals that don’t trigger competition issues, but with the caveat that certain conditions apply.
SHANGHAI – Bayer AG’s recent purchase of traditional Chinese medicine (TCM) maker Dihon Pharmaceutical Group Co. was viewed by some as a step closer to the legitimization of the TCM drug market, one that occupies about a third to a half of all revenues here.
SHANGHAI – China continues to entice and confound those looking for the right opportunity to invest in its rapidly changing health care sector. At the 5th China Healthcare Investment Conference held in Shanghai, biotech stood out as the key opportunity among numerous strategies discussed.
SHANGHAI – Bayer AG is buying Dihon Pharmaceutical Group Co. located China’s southwest Yunnan province. Privately held Dihon makes OTC and traditional Chinese medicines (TCM) sold in China and Southeast Asia.
HONG KONG – After a rocky year for many biopharma companies in China hit hard by bribery investigations companies may find some hopeful points in the overall trend of stricter supervision and punishment in the government’s list of priorities for health care enforcement.
SHANGHAI – Privately held Shanxi Taxus Pharmaceuticals Co. Ltd., a subsidiary of Shenzhen Forntsea Taxus Industry Capital Management, will acquire majority shares in innovative drug developer Cardium Therapeutics Inc. (CRXM), of San Diego, for $5 million in cash.
SHANGHAI – In the summer of China’s pharma scandal there was one constant: whistleblowers and their allegations of corruption backed by insider knowledge.
